HealthInvest Partners’s Evolus EOLS Stock Holding History

HealthInvest Partners’s Portfolio EOLS Stock Details EOLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-300,000	Closed	-$2.29M	–	16
2021 Q3	$2.29M	Buy	+300,000	New	+$3.1M	3.42%	10

Other funds holding EOLS

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

AWH Capital Dallas, Texas $110M AUM 44.24% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HealthInvest Partners's EOLS Position: Q4 2021 in Review

HealthInvest Partners sold out of Evolus (EOLS) in Q4 2021, closing a stake of 300,000 shares — an estimated $2.29M sold.

HealthInvest Partners first reported a position in EOLS in Q3 2021 and held it in 1 quarter. The position peaked at $2.29M in Q3 2021. 104 funds tracked by Wall St. Rank hold EOLS as of Q4 2021.

HealthInvest Partners reported no remaining Evolus position as of Q4 2021 after selling out during the quarter.
HealthInvest Partners sold 300,000 Evolus shares in Q4 2021, an estimated $2.29M.
HealthInvest Partners first reported a position in Evolus in Q3 2021 and held it in 1 quarter.
HealthInvest Partners's Evolus position peaked at $2.29M in Q3 2021.
104 funds tracked by Wall St. Rank held Evolus as of Q4 2021.

Based on HealthInvest Partners's 13F filing for Q4 2021, filed 18 Jan 2022.